<DOC>
	<DOCNO>NCT00565708</DOCNO>
	<brief_summary>We hypothesize randomize , placebo-controlled adjuvant study , Aspirin patient dukes C high risk duke B colorectal cancer ( ASCOLT ) improve survival patient population placebo control . If indeed find beneficial , aspirin cheap easy administer , positively impact live many individual Asia globally . STUDY OBJECTIVE To assess effectiveness Aspirin placebo control patient dukes C high risk duke B colorectal cancer term Disease Free Survival ( DFS ) Overall Survival ( OS ) Primary endpoint - DFS among eligible subject ( high risk Dukes B colon cancer , Dukes C colon cancer rectal cancer patient sub-groups ) ; - DFS among patient colon cancer ( high-risk Dukes B Dukes C colon cancer ) . Secondary endpoint - Overall survival ( OS ) 5 year - DFS OS - Chinese , Malay , Indian ethnic group - Resected high risk Dukes B colon cancer , Dukes C colon cancer rectal cancer sub-groups , individually - Compliant versus non-compliant subject - PIK3CA mutate tumor ( sample available )</brief_summary>
	<brief_title>Aspirin Dukes C High Risk Dukes B Colorectal Cancers</brief_title>
	<detailed_description>Aspirin patient dukes C high risk duke B colorectal cancer improve survival patient population placebo control . Eligible patient randomize treatment arm , use follow stratification factor : - Study Centre - Tumour Type - Type adjuvant chemotherapy receive ( exposed/not expose oxaliplatin Patients randomize 5 year ' time period . After randomization , patient 3 monthly assessment treatment 3 year follow 6 monthly assessment additional 2 year follow-up</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Inclusion Criteria Male female outpatient ≥ 18 year age ≥ country 's legal age adult consent Dukes C colon cancer , high risk Dukes B colon cancer , Dukes B rectal cancer Dukes C rectal cancer ( see Appendix 1 definition High Risk Dukes B ) Undergone complete resection primary tumour Completed standard therapy ( least 3 month chemotherapy ± radiotherapy ) Within 120 day completion standard therapy ( surgery , chemotherapy ± radiotherapy ) ECOG performance status 0 2 Satisfactory haematological biochemical function ( test carry within 8 week prior randomisation ) : Results clinical investigation carry within 8 week prior randomisation use place require screening investigation . Patients mild laboratory abnormality include discretion site principal investigator , approval ASCOLT Trial Management Group ANC ≥ 1.0 x 109/L Platelets ≥ 100 x 109/L Creatinine clearance ≥ 30 mL/min Total bilirubin ≤ 2.0 x upper limit normal AST &amp; ALT ≤ 5 x upper limit normal Completed follow investigation Colonoscopy ( CT colonogram ( within 16 month prior randomization ) Imaging abdomen ( CT CT colonogram MRI PET Ultrasound ) within 16 month prior randomization Written inform consent Exclusion Criteria Preexisting Familial adenomatous polyposis , inflammatory bowel disease ulcerative colitis Active gastritis active peptic ulcer History continuous daily use PPI 1 year prior consent Gastrointestinal bleeding within past one year Haemorrhagic diathesis ( i.e . haemophilia ) Uncontrolled hypertension ( untreated systolic blood pressure &gt; 160 mmHg , diastolic blood pressure &gt; 95 mmHg ) History recent cancer ( except colorectal cancer , nonmelanoma skin cancer , basal cell carcinoma , squamous cell carcinoma ) past 5 year History stroke , coronary arterial disease , angina , vascular disease Patients current long term treatment ( ≥ 4 consecutive week ) Aspirin , NSAID Cox2 inhibitor History erosive GERD active erosive GERD gastroscopy . Patient active current treatment antiplatelet agent ( i.e . offstudy Aspirin , clopidogrel , ticlopidine ) Patient receive active treatment anticoagulant ( i.e . warfarin , low molecular weight heparin ) Pregnant , lactating , use adequate contraception Patient know allergy NSAID Aspirin Unexplained rise CEA ( i.e . smoker elevate CEA exclude ) Patient investigational drug Patients HNPCC ( Lynch Syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
</DOC>